Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2…
<!-- Name:DistributionId Value:8790218 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Nasdaq:JNCE
Redx and Jounce Announce Recommended Business Combination
<!-- Name:DistributionId Value:8755246 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Jounce Therapeutics Reports Results from Phase 2 Randomized SELECT Trial Testing 2…
- SELECT trial of vopratelimab in combination with pimivalimab versus pimivalimab alone did not meet its primary endpoint of mean tumor change averaged over 9 and 18 weeks - - Encouraging…